Lobbying: all issues, rounded to the nearest $10,000. Two filers, same 21 months. This PAC gives money raised from the company’s employees; the company itself can’t give to campaigns from its treasury.
Spend by quarter Pro
Free account See ProWhat they lobby on
MethodGenentech reported federal lobbying in 8 of the last 8 quarters (Q4 2024 to Q3 2026), with its own in-house lobbyists and 15 outside firms. What follows is what the filings say it lobbied on, not which way.
Issue areas ranked by quarters filedQ4 24 → Q3 26
- Budget/Appropriations8/8
- Copyright/Patent/Trademark8/8
- Health Issues8/8
- Immigration8/8
- Manufacturing8/8
Medical/Disease Research/Clinical Labs 8 of 8 · Medicare/Medicaid 8 of 8 · 3 more · Show all 10
- Medical/Disease Research/Clinical Labs8/8
- Medicare/Medicaid8/8
- Pharmacy8/8
- Taxation/Internal Revenue Code8/8
- Trade (domestic/foreign)8/8
Bills named in the filings 36 bills, this period
- H.R. 1492 To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.11 filings
- H.R. 4299 Protecting Patient Access to Cancer and Complex Therapies Act9 filings
- S. 1041 Affordable Prescriptions for Patients Act5 filings
- S. 1040 Drug Competition Enhancement Act4 filings
- H.R. 3269 ETHIC Act3 filings
31 more, 24 named in only one filing · Show all 36
- H.R. 3290, 118th 340B Transparency Act3 filings
- H.Con.Res. 14 Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. Broad bill3 filings
- H.R. 7148 Consolidated Appropriations Act, 2026 Broad bill3 filings
- S.Con.Res. 7 An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. Broad bill3 filings
- H.R. 9504 Tax Exempt Hospital Transparency Act2 filings
- H.R. 9599 SECURE 340B Act2 filings
- H.R. 7024, 118th Tax Relief for American Families and Workers Act of 2024 Broad bill2 filings
- H.R. 1672 Maintaining Investments in New Innovation Act1 filing
- H.R. 2679, 118th Pharmacy Benefits Manager Accountability Act1 filing
- H.R. 2882 Central Coast of California Conservation Act of 20251 filing
- H.R. 3599 Joint Reserve Detachment (JRD) Formalization Act1 filing
- H.R. 4822, 118th Health Care Price Transparency Act of 20231 filing
- H.R. 5391, 118th Protecting Patient Access to Cancer and Complex Therapies Act1 filing
- S. 1096 Preserve Access to Affordable Generics and Biosimilars Act1 filing
- S. 113, 118th Prescription Pricing for the People Act of 20231 filing
- S. 142, 118th Preserve Access to Affordable Generics and Biosimilars Act1 filing
- S. 148, 118th Stop STALLING Act1 filing
- S. 150, 118th Affordable Prescriptions for Patients Act of 20231 filing
- S. 2333, 118th Pandemic and All-Hazards Preparedness and Response Act1 filing
- S. 2764, 118th Protecting Patient Access to Cancer and Complex Therapies Act of 20231 filing
- S. 476 / H.R. 5547, 118th Maintaining Investments in New Innovation Act1 filing
- S. 652 / H.R. 2630, 118th Safe Step Act1 filing
- S. 79, 118th Interagency Patent Coordination and Improvement Act of 20231 filing
- H.R. 1 An act to provide for reconciliation pursuant to title II of H. Con. Res. 14. Broad bill1 filing
- H.R. 10445, 118th Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 Broad bill1 filing
- H.R. 2673, 118th American Innovation and R&D Competitiveness Act of 2023 Broad bill1 filing
- H.R. 5376, 118th Share the Savings with Seniors Act Broad bill1 filing
- H.R. 5378, 118th Lower Costs, More Transparency Act Broad bill1 filing
- S. 127, 118th Pharmacy Benefit Manager Transparency Act of 2023 Broad bill1 filing
- S. 1339, 118th Pharmacy Benefit Manager Reform Act Broad bill1 filing
- S. 866, 118th American Innovation and Jobs Act Broad bill1 filing
From the filings
“H.R. 3599, SECURE 340B Act, Issues related to drug pricing and patient access”
“Issues related to corporate taxation including corporate rate; deductibility of research and development expenses; and international taxation (Foreign Derived Intangible Income). P.L. 119-21.”
Contacted as listed on the filings
- U.S. House
- U.S. Senate
- CMS
- FDA
- HHS
- DHS
- DOL
- PTO
- Treasury
- USTR
- White House Office
- CDC
The House and Senate appear in every quarter; agencies in all 8 quarters.
Every filing since 2015 Pro
Free account See ProSource: Lobbying Disclosure Act filings (LD-2) by Genentech, Senate Office of Public Records. Filings are due 20 days after each quarter ends.
From FEC filings: direct gifts this PAC reported, net of refunds · How we count
Gave directly to 110 sitting members of Congress and 2 other candidates in 2025–26.
See every candidate and member Genentech gave to directly, how much, and how its money splits between the parties.
This part is in Pro. A free account lets you follow up to 3 people and get a weekly email about them; upgrade whenever you need more.
Create a free account See what Pro adds Log in